A Study of LP-118 In Combination With Ponatinib, Dexamethasone And Blinatumomab For Adults With Newly-Diagnosed, BCR::ABL1-Positive Acute Lymphoblastic Leukemia (ALL)

The purpose of this research study is to see if a drug called LP-118 is safe and effective for treating adults with Philadelphia chromosome-positive (Ph+) B cell acute lymphoblastic leukemia (ALL), when given with ponatinib, dexamethasone, methotrexate and blinatumomab (the standard treatment for this type of cancer).

Trial Details

NCT ID

NCT07614022

Phase

PHASE1

Sponsor

Wake Forest University Health Sciences

Status

RECRUITING

Cancer Type

Leukemia

Interventions

LP-118

Locations (sample)

Charlotte, North Carolina, United States|35.22709,-80.84313
Winston-Salem, North Carolina, United States|36.09986,-80.24422

Key Eligibility Criteria

Ability to understand and willingness to sign an IRB-approved informed consent.
Age ≥ 18 years at the time of consent.
ECOG Performance Status (PS) ≤ 2.
Histological or cytological confirmation of newly diagnosed CD19-positive Philadelphia-chromosome/BCR::ABL1-positive ALL.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Leukemia Trials on Trialify →